Clinical Report: New Clues to Crohn's Genetic Risk
Overview
This study presents a high-resolution map of gene regulatory interactions in human ILC3s, identifying candidate genes linked to Crohn's disease.
Background
Crohn's disease is a complex inflammatory bowel disease with significant clinical variability, influenced by genetic factors. This research aims to clarify the role of noncoding genetic variants in Crohn's disease through detailed gene regulatory mapping.
Data Highlights
The study identified 109 candidate genes in ILC3s and 118 in CD4-positive T cells associated with Crohn's disease, including established immune-related genes and novel candidates.
Key Findings
- High-resolution promoter capture Hi-C maps were generated from primary human ILC3s.
- Thousands of promoter-enhancer interactions were identified, revealing differences in gene regulatory networks between ILC3s and CD4-positive T cells.
- More than half of the prioritized genes had not been previously linked to inflammatory bowel disease.
- CLN3 was identified as a novel gene influencing ILC3 function and inflammatory response.
- The approach was also applied to other immune-mediated diseases, indicating a broader role for ILC3s.
Clinical Implications
The findings provide a resource for interpreting GWAS signals and may assist in identifying candidate genes for functional validation in Crohn's disease.
Conclusion
This study offers insights into the genetic basis of Crohn's disease.
Related Resources & Content
- The pathologist, The Pathologist, 2026 -- Genes Predict Bowel Disease Severity
- Frontiers in Immunology, Frontiers in Immunology, 2026 -- Spatial genetic mapping links shared inflammatory bowel disease liability to adult immune–epithelial lesion contexts
- The New Gastroenterologist, The New Gastroenterologist, 2025 -- Blood Test Shows Potential to Forecast Crohn’s Disease Two Years Prior to Diagnosis
- Pharmacological management of moderate-to-severe Crohn’s disease - American Gastroenterological Association, American Gastroenterological Association, 2025 -- Pharmacological management of moderate-to-severe Crohn’s disease
- Blood Cancer Journal — Functional Assessment and Validation of GWAS-Identified Genetic Variants Linked to Chronic Lymphocytic Leukemia: Insights from the CRuCIAL Study
- Pharmacological management of moderate-to-severe Crohn’s disease - American Gastroenterological Association
- Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study - PubMed
- Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn’s Disease: A Systematic Literature Review and Network Meta-Analysis | Advances in Therapy | Springer Nature Link
Based on findings from:
New Clues to Crohn's Genetic Risk
The Pathologist, 2026.
https://www.thepathologist.com/issues/2026/articles/august/new-clues-to-crohns-genetic-risk/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
